The initiation of coverage by Exane BNP Paribas with an Underperform rating suggests a bearish outlook on IBM's stock in the short term. The price target of $145, depending on the current trading price, may indicate a downside potential. Analyst ratings can significantly influence market perception and investor sentiment, potentially leading to a decrease in stock price.